metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P-58 PREVALENCE OF CHRONIC VIRAL HEPATITIS TYPE C IN PEOPLE DEPRIVED OF THEIR LI...
Información de la revista
Vol. 28. Núm. S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(marzo 2023)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 28. Núm. S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(marzo 2023)
Acceso a texto completo
P-58 PREVALENCE OF CHRONIC VIRAL HEPATITIS TYPE C IN PEOPLE DEPRIVED OF THEIR LIBERTY IN THE CERESOS OF THE STATE OF VERACRUZ, MEXICO: TOWARDS MICRO-ELIMINATION
Visitas
179
María Teresa Guzmán Terrones1, Ignacio Manuel Pérez Acosta2, Mauricio Alfaro Centeno3
1 Head of The Hepatitis Clinic, High Specialty Hospital Veracruz, Veracruz, México
2 4th-year Resident of Internal Medicine, Hospital Issste Veracruz, Veracruz, México
3 Medical of Social Service, Cristóbal Colón University, Veracruz, México
Este artículo ha recibido
Información del artículo
Suplemento especial
Este artículo forma parte de:
Vol. 28. Núm S1

Abstracts of the 2022 Annual Meeting of the ALEH

Más datos
Introduction and Objectives

By the finally of the WHO Strategy for the control and elimination of Chronic Viral Hepatitis Type C (HCV) by 2030, persons deprived of their liberty (PPL) are a key population due to the high prevalence reported in prisons. This study aimed to determine the prevalence of HCV of PPL in the 17 Social Rehabilitation Centers (CERESO's) of the State to treat with Direct Action Antivirals (DAA) and to identify the risk factors in this population.

Patients and Methods

Descriptive, cross-sectional, observational study in 17 CERESO from Veracruz, Mexico, to 6466 PPL, through screening from 2019 to the present. APRI/FIB4 index, glomerular filtration rate, HIV, comorbidities, and related risk factors were determined. Post-screening, 31 patients were treated with DAAs with sofosbuvir/velpatasbir and 5 with glecaprevir/pibrentasvir with sustained viral response in all patients.

Results

An incidence of HCV in PPL of 0.6% (36 patients) was found, with a prevalence of 0.05% (4 patients) to date, which have already received treatment with DAAs. 100% were men without HIV. As risk factors, 69% of the PPL used intranasal or intravenous psychoactive substances (UDIS), and 61% had piercings and/or tattoos. 80.6% did not have a school education or did not mention it, and only 14% had completed primary school. The population with the highest risk was between 30 and 39 years old (49%). Determined APRI/FIB-4, only 5 patients were staged F3 and 1 F4.

Conclusions

The prevalence of HCV in PPL in CERESOs of Veracruz, Mexico, is lower than that reported in the world literature, which is explained by the consumption of only 0.4% of UDIS, which stands as the main risk factor for prevalence. In previous reports, the majority of the population are men within the age group of 30 to 39 years, lower than previously found.

El Texto completo está disponible en PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos